Want to see HK:2219 full AI Analyst Report?
Top Page
Chaoju Eye Care Holdings Ltd.
(2219)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$3.00
▲(18.11% Upside)
Action:Reiterated
Date:08/06/26
The score is supported most by attractive valuation (low P/E and high dividend yield) and a strong, low-leverage balance sheet. These positives are tempered by weaker recent operating trends (2025 revenue decline, margin compression) and notably softer/volatile free cash flow, while technical indicators suggest only modest, neutral-to-slightly-positive momentum.
Positive Factors
Solid Profitability
Healthy gross, operating, and net margins show that core ophthalmic services remain economically attractive. This profitability provides capacity to fund clinical operations and expansion, although sustaining margins will depend on restoring growth and controlling costs.
Negative Factors
Revenue Contraction
The reversal from growth to contraction indicates weaker recent patient volumes, pricing, or service mix. If sustained, lower revenue would reduce operating leverage and make it harder to expand the hospital network while preserving profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid Profitability
Healthy gross, operating, and net margins show that core ophthalmic services remain economically attractive. This profitability provides capacity to fund clinical operations and expansion, although sustaining margins will depend on restoring growth and controlling costs.
Read all positive factors
Chaoju Eye Care Holdings Ltd. (2219) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.78B
Dividend Yield9.52%
Average Volume (3M)256.10K
Price to Earnings (P/E)9.1
Beta (1Y)0.72
Revenue Growth3.85%
EPS Growth-1.23%
CountryHK
Employees2,590
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.24
Shares Outstanding701,460,000
10 Day Avg. Volume515,436
30 Day Avg. Volume256,096
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)0.72
Price to Sales (P/S)1.27
P/FCF Ratio15.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)HK$1.47B
Chaoju Eye Care Holdings Ltd. Business Overview & Revenue Model
Company Description
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyop...
How the Company Makes Money
Chaoju Eye Care Holdings generates revenue primarily by providing paid ophthalmic medical services to patients through its hospitals and clinics. Its core revenue streams typically include: (1) surgical and procedure-based services (e.g., refracti...
Chaoju Eye Care Holdings Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.36B | 1.41B | 1.37B | 990.04M | 997.79M |
| Gross Profit | 563.79M | 573.90M | 611.30M | 621.13M | 434.70M | 448.67M |
| EBITDA | 334.81M | 331.03M | 335.37M | 434.82M | 267.87M | 304.65M |
| Net Income | 164.63M | 183.44M | 195.08M | 228.91M | 187.75M | 161.75M |
Balance Sheet | ||||||
| Total Assets | 2.97B | 3.02B | 2.88B | 2.92B | 2.72B | 2.51B |
| Cash, Cash Equivalents and Short-Term Investments | 1.40B | 1.49B | 1.54B | 1.55B | 1.68B | 1.78B |
| Total Debt | 249.02M | 237.74M | 218.01M | 200.80M | 196.16M | 178.65M |
| Total Liabilities | 648.55M | 612.92M | 554.76M | 544.38M | 424.68M | 378.11M |
| Stockholders Equity | 2.32B | 2.40B | 2.32B | 2.36B | 2.27B | 2.11B |
Cash Flow | ||||||
| Free Cash Flow | 143.82M | 112.58M | 354.36M | 286.02M | 148.29M | 189.18M |
| Operating Cash Flow | 332.50M | 339.41M | 354.36M | 372.57M | 273.41M | 249.39M |
| Investing Cash Flow | -211.08M | -460.60M | 245.36M | -654.10M | -464.77M | -578.51M |
| Financing Cash Flow | -202.13M | -132.87M | -292.30M | -204.01M | -165.43M | 1.19B |
Chaoju Eye Care Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.78B | 9.07 | 6.97% | 9.52% | 3.85% | -1.23% | |
67 Neutral | HK$1.05B | 9.86 | 5.57% | 2.35% | 4.75% | ― | |
66 Neutral | HK$751.47M | 305.19 | 0.20% | 1.88% | 20.54% | -96.74% | |
60 Neutral | HK$1.03B | 31.31 | 1.27% | ― | ― | ― | |
54 Neutral | HK$469.86M | -145.42 | -0.41% | ― | 3.16% | -101.02% | |
53 Neutral | HK$1.18B | 86.19 | 0.48% | 0.99% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2219
Chaoju Eye Care Holdings Ltd.
2.55
0.03
1.19%
HK:1846
EuroEyes International Eye Clinic Limited
2.35
-0.61
-20.47%
HK:3309
C-MER Eye Care Holdings Limited
0.83
-1.05
-55.87%
HK:3869
Hospital Corporation of China Ltd
3.40
-3.39
-49.93%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-30.92%
HK:6639
Arrail Group Ltd.
1.83
-0.44
-19.43%
Chaoju Eye Care Holdings Ltd. Corporate Events
Chaoju Eye Care Sets August Board Meeting to Approve Interim Results and Mull Dividend
Aug 13, 2026
Chaoju Eye Care Holdings Limited has scheduled a board meeting for August 28, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider whet...
Chaoju Eye Care Adds USD16 Million Structured Deposit in Treasury Strategy
Jul 23, 2026
Chaoju Eye Care (HK) Company Limited, an indirect wholly owned unit of Chaoju Eye Care Holdings, has subscribed to a USD16 million structured deposit product linked to 10-year Chinese government bond yields offered by JPMorgan Chase Bank, with a t...
Chaoju Eye Care Deploys USD31.8 Million Into JPMorgan Structured Deposit
Jun 10, 2026
Chaoju Eye Care (HK) Company Limited, an indirect wholly owned unit of Chaoju Eye Care Holdings, has subscribed to a principal-guaranteed structured deposit product worth USD31.8 million offered by JPMorgan Chase Bank, funded entirely by surplus c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.